The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with diabetes mellitus

Chronic inflammatory demyelinating polyneuropathy (CIDP) in patients with diabetes mellitus (DM) occurs approximately 9—11 times more frequently than in the general population.

Objective: to assess the characteristics of CIDP in the presence of DM.

Patients and methods. A total of 109 patients with CIDP diagnosed according to the international EFNS/PNS criteria were examined. Seventeen patients had type 1 or 2 DM; the remaining 92 patients did not.

Results and discussion. The patients with CIDP and DM were found to have significantly more obvious neurological deficit, lower levels of selfservice, and a shorter time to diagnose CIDP than those with CIDP without DM.

The concurrence of CIDP and DM is ambiguously assessed. On the one hand, there are indications of a strict correlation between these conditions, and on the other, the absence of this association. Our study showed that more obvious neurological deficit in DM can be related to the additional damaging impact of chronic hyperglycemia as impaired metabolism of nerve fibers and deterioration of their trophism. The autoimmune nerve damage occurring in CIDP is superimposed on the already existing impairments in the microcirculation and dysfunction of peripheral nerves, thereby increasing their damage.

Conclusion. The course of CIDP in the presence of DM differs from that of «pure» CIDP, which should be taken into account in managing these patients.

1. Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016 Sep-Oct;30(7):1401-7. doi: 10.1016/j.jdiacomp.2016.05.007. Epub 2016 May 10.

2. Khoo A, Frasca J, Schultz D. Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Biomark Res. 2019 Feb 12;7:3. doi: 10.1186/s40364-019-0154-2. eCollection 2019.

3. Broers MC, Bunschoten C, Nieboer D, et al. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-172. doi: 10.1159/000494291. Epub 2019 Jan 22.

4. Tursynov NI, Grigolashvili MA, Iluyshina NYu, et al. Modern aspects of diagnosis and treatment of chronic demyelinated polyneuropathies. Neirokhirurgiya i nevrologiya Kazakhstana. 2016;(3):38-45. (In Russ.).

5. Rajabally YA, Stettner M, Kieseier BC, et al. Peripheral neuropathies, CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. Nat Rev Neurol. 2017 Oct;13(10):599-611. doi: 10.1038/nrneurol.2017.123. Epub 2017 Sep 15.

6. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol. 2010 Mar;17(3):356-63. doi: 10.1111/j.1468-1331.2009.02930.x.

7. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997 Jul;49(1):229-39.

8. Alabdali M, Abraham A, Alsulaiman A, et al. Clinical characteristics , and impairment and disability scale scores for different CIDP Disease Activity Status classes. J Neurol Sci. 2017 Jan 15;372:223-227. doi: 10.1016/j.jns.2016.11.056. Epub 2016 Nov 23.

9. Kleyweg RP, Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength guillain-barre syndrome. Muscle Nerve. 1991 Nov;14(11):1103-9.

10. Prodinger B, O'Connor RJ, Stucki G, Tennant A. Establishing score equivalence of the functional independence measure motor scale and the barthel index, utilizing the International classification of functioning, disability and health and rasch measurement theory. J Rehabil Med. 2017 May 16;49(5): 416-22. doi: 10.2340/16501977-2225.

11. Laughlin RS, Dyck PJ, Melton LJ, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009 Jul 7;73(1):39-45. doi: 10.1212/WNL.0b013e3181aaea47.

12. Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007 Dec; 78(12):1349-53. Epub 2007 May 10.

13. Abraham A, Albulaihe H, Alabdali M, et al. Elevated vibration perception thresholds in CIDP patients indicate more severe neuropathy and lower treatment response rates. PLoS One. 2015 Nov 6;10(11):e0139689. doi: 10.1371/journal.pone.0139689. eCollection 2015.

14. Sharma KR, Cross J, Farronay O, et al. Demyelinating Neuropathy in Diabetes Mellitus. Arch Neurol. 2002. 59: 758-65. https://doi.org/10.1001/archneur.59.5.758.

15. Dunnigan SK, Ebadi H, Breiner A et al. The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes - An Observational Study. PLoS One. 2014 Feb 19;9(2):e89344. doi: 10.1371/journal.pone.0089344. eCollection 2014.

16. Finsterer J, Aliyev R. Chronic inflammatory demyelinating polyneuropathy variant with creatine-kinase elevation and vanishing effect of immunoglobulins. Am J Case Rep. 2017 Jul 27;18:834-838.

17. Nevoret M, Vinik AI. CIDP variants in diabetes: measuring treatment response with a small nerve fi ber test. J Diabetes Complications. 2015 Mar;29(2):313-7. doi: 10.1016/j.jdiacomp.2014.10.012. Epub 2014 Nov 6.

18. Dunnigan SK, Ebadi H, Breiner A, et al. Comparison of diabetes patients with «demyeli-nating» diabetic sensorimotor polyneuropathy to those diagnosed with CIDP. Brain Behav. 2013 Nov;3(6):656-63. doi: 10.1002/brb3.177. Epub 2013 Sep 22.

19. Lotan I, Hellman MA, Steiner I. Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus. Acta Neurol Scand. 2015 Oct;132(4):278-83. doi: 10.1111/ane.12394. Epub 2015 Mar 25.